All In Biotech

Drug Trial Radar · NCT07415252

SkyVaricella® (NBP608) Vaccine With Lower Potencies in Healthy Children Aged 12 Months to 12 Years

A Phase III, Randomized, Double-blinded, Active-controlled, Multinational, Multicenter Study to Assess the Safety and Immunogenicity of a Two-dose Regimen of SKYVaricella® (NBP608) in Children Aged 12 Months to 12 Years

Last checked: Nov 19, 2026Latest source record: Sep 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 780 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

780

Planned (sponsor's estimate)

Start

Jul 4, 2026

Primary completion

Feb 13, 2027

Study completion Jan 2, 2028

Sponsor

Lead sponsor
SK Bioscience Co., Ltd.Industry
Sponsor type
Industry
First posted
Feb 17, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 12 months, up to 12 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The goal of this study is to evaluate the safety and immunogenicity of an investigational varicella vaccine in children. Researchers will compare the investigational vaccine, NBP608, with licensed varicella vaccines. The study includes children aged 12 months to 12 years. Participants will be randomly assigned to receive either the investigational vaccine (NBP608) or licensed varicella vaccines. Participants will: Receive two subcutaneous injections of a study vaccine administered. Visit the study clinic seven times over approximately 15 months. Receive follow-up phone calls 7 days after each vaccination to monitor for safety.

Conditions

  • Varicella (Chickenpox)

Interventions

  • NBP608 (Mid Potency)Biological

    NBP608 (mid potency) is a live attenuated varicella virus vaccine (Oka/SK strain).

  • NBP608 (Low Potency)Biological

    NBP608 (low potency) is a live attenuated varicella virus vaccine (Oka/SK strain).

  • Varivax®Biological

    Varivax® is a licensed live attenuated varicella virus vaccine (Oka/Merck strain).

  • SKYVaricella®Biological

    SKYVaricella® is a licensed live attenuated varicella virus vaccine (Oka/SK strain).

  • Normal Saline (Placebo)Other

    Placebo consisting of normal saline (0.9% sodium chloride solution).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Seroconversion rate of varicella-zoster virus(VZV)Time frame: 6 weeks after each dose.
  2. Geometric mean antibody titer (GMT) of varicella-zoster virus(VZV) IgG antibodiesTime frame: 6 weeks after the second dose.

Locations

14 sites in 4 countries. Site status is shown where the registry gives one.

  • San Pedro Sula, site 101

    San Pedro Sula, Cortés Department, Honduras · Not yet recruiting

  • Tegucigalpa, site 102

    Tegucigalpa, Francisco Morazán Department, Honduras · Recruiting

  • Manila, site 301

    Manila, National Capital Region, Philippines · Recruiting

  • Quezon City, site 302

    Quezon City, National Capital Region, Philippines · Recruiting

  • Quezon City, site 303

    Quezon City, National Capital Region, Philippines · Recruiting

  • Daegu, site 404

    Daegu, Daegu, South Korea · Recruiting

  • Ansan, site 401

    Ansan, Gyeonggi-do, South Korea · Recruiting

  • Hwaseong-si, site 406

    Hwaseong-si, Gyeonggi-do, South Korea · Not yet recruiting

  • Seongnam-sit, site 405

    Seongnam-si, Gyeonggi-do, South Korea · Not yet recruiting

  • Incheon, site 403

    Incheon, Incheon, South Korea · Recruiting

  • Seoul, site 402

    Seoul, Seoul, South Korea · Recruiting

  • Seoul, site 408

    Seoul, Seoul, South Korea · Not yet recruiting

  • Seoul, site 407

    Seoul, Seoul, South Korea · Not yet recruiting

  • Khon Kaen City, site 201

    Khon Kaen, Changwat Khon Kaen, Thailand · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.